Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports

Open Access 18-01-2024 | Alzheimer's Disease

Mind Gaps and Bone Snaps: Exploring the Connection Between Alzheimer’s Disease and Osteoporosis

Authors: Hannah S. Wang, Sonali J. Karnik, Tyler J. Margetts, Lilian I. Plotkin, Alexandru Movila, Jill C. Fehrenbacher, Melissa A. Kacena, Adrian L. Oblak

Published in: Current Osteoporosis Reports

Login to get access

Abstract

Purpose of Review

This comprehensive review discusses the complex relationship between Alzheimer’s disease (AD) and osteoporosis, two conditions that are prevalent in the aging population and result in adverse complications on quality of life. The purpose of this review is to succinctly elucidate the many commonalities between the two conditions, including shared pathways, inflammatory and oxidative mechanisms, and hormonal deficiencies.

Recent Findings

AD and osteoporosis share many aspects of their respective disease-defining pathophysiology. These commonalities include amyloid beta deposition, the Wnt/β-catenin signaling pathway, and estrogen deficiency. The shared mechanisms and risk factors associated with AD and osteoporosis result in a large percentage of patients that develop both diseases. Previous literature has established that the progression of AD increases the risk of sustaining a fracture. Recent findings demonstrate that the reverse may also be true, suggesting that a fracture early in the life course can predispose one to developing AD due to the activation of these shared mechanisms. The discovery of these commonalities further guides the development of novel therapeutics in which both conditions are targeted.

Summary

This detailed review delves into the commonalities between AD and osteoporosis to uncover the shared players that bring these two seemingly unrelated conditions together. The discussion throughout this review ultimately posits that the occurrence of fractures and the mechanism behind fracture healing can predispose one to developing AD later on in life, similar to how AD patients are at an increased risk of developing fractures. By focusing on the shared mechanisms between AD and osteoporosis, one can better understand the conditions individually and as a unit, thus informing therapeutic approaches and further research. This review article is part of a series of multiple manuscripts designed to determine the utility of using artificial intelligence for writing scientific reviews.
Literature
1.
2.
3.
Tsai CH, et al. Fracture as an independent risk factor of dementia: a nationwide population-based cohort study. Medicine (Baltimore). 2014;93(26): e188.PubMedCrossRef
4.
Friedman SM, et al. Dementia and hip fractures: development of a pathogenic framework for understanding and studying risk. Geriatr Orthop Surg Rehabil. 2010;1(2):52–62.PubMedPubMedCentralCrossRef
5.
Lui LY, et al. Bone loss predicts subsequent cognitive decline in older women: the study of osteoporotic fractures. J Am Geriatr Soc. 2003;51(1):38–43.PubMedCrossRef
6.
Yuan J, et al. The potential influence of bone-derived modulators on the progression of Alzheimer’s disease. J Alzheimers Dis. 2019;69(1):59–70.PubMedCrossRef
7.
8.
9.
10.
11.
12.
Armstrong RA. The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer’s disease. Folia Neuropathol. 2009;47(4):289–99.PubMed
13.
Xia WF, et al. Swedish mutant APP suppresses osteoblast differentiation and causes osteoporotic deficit, which are ameliorated by N-acetyl-L-cysteine. J Bone Miner Res. 2013;28(10):2122–35.PubMedCrossRef
14.
Paris D, et al. Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neurosci Lett. 2004;366(1):80–5.PubMedCrossRef
15.
16.
Metcalfe MJ, Figueiredo-Pereira ME. Relationship between tau pathology and neuroinflammation in Alzheimer’s disease. Mt Sinai J Med. 2010;77(1):50–8.PubMedPubMedCentralCrossRef
17.
18.
• van Dyck CH, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9–21. This study reported a reduction in cognitive and functional decline in AD patients treated with lecanemab, a new monoclonal antibody that targets amyloid beta-soluble protofibrils.
19.
Sarafrazi N, Wambogo EA, Shepherd JA. Osteoporosis or low bone mass in older adults: United States, 2017–2018. NCHS Data Brief. 2021;405:1–8.
20.
Sozen T, Ozisik L, Basaran NC. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4(1):46–56.PubMedCrossRef
21.
•• JE LL, et al. Degradation of bone quality in a transgenic mouse model of Alzheimer’s disease. J Bone Miner Res. 2022;37(12):2548–65. https://​doi.​org/​10.​1002/​jbmr.​4723. This primary research study utilized a 5xFAD transgenic model of AD to establish a relationship between elevated Aβ levels and impairment of bone health in mice.
22.
Dengler-Crish CM, Elefteriou F. Shared mechanisms: osteoporosis and Alzheimer’s disease? Aging (Albany NY). 2019;11(5):1317–8.PubMedCrossRef
23.
Weller II. The relation between hip fracture and Alzheimer’s disease in the canadian national population health survey health institutions data, 1994–1995 A cross-sectional study. Ann Epidemiol. 2000;10(7):461.PubMedCrossRef
24.
Chen YH, Lo RY. Alzheimer’s disease and osteoporosis. Ci Ji Yi Xue Za Zhi. 2017;29(3):138–42.PubMed
25.
Hu H, et al. No genetic causal association between Alzheimer’s disease and osteoporosis: a bidirectional two-sample Mendelian randomization study. Front Aging Neurosci. 2023;15:1090223.PubMedPubMedCentralCrossRef
26.
Jia L, Pina-Crespo J, Li Y. Restoring Wnt/beta-catenin signaling is a promising therapeutic strategy for Alzheimer’s disease. Mol Brain. 2019;12(1):104.PubMedPubMedCentralCrossRef
27.
Garcia-Velazquez L, Arias C. The emerging role of Wnt signaling dysregulation in the understanding and modification of age-associated diseases. Ageing Res Rev. 2017;37:135–45.PubMedCrossRef
28.
De Ferrari GV, et al. Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer’s disease. Proc Natl Acad Sci U S A. 2007;104(22):9434–9.PubMedPubMedCentralCrossRef
29.
Alarcon MA, et al. A novel functional low-density lipoprotein receptor-related protein 6 gene alternative splice variant is associated with Alzheimer’s disease. Neurobiol Aging. 2013;34(6):1709.e9-18.PubMedCrossRef
30.
Liu CC, et al. Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer’s disease. Neuron. 2014;84(1):63–77.PubMedPubMedCentralCrossRef
31.
32.
Pederson L, et al. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A. 2008;105(52):20764–9.PubMedPubMedCentralCrossRef
33.
Henriksen K, et al. Local communication on and within bone controls bone remodeling. Bone. 2009;44(6):1026–33.PubMedCrossRef
34.
Martin T, Gooi JH, Sims NA. Molecular mechanisms in coupling of bone formation to resorption. Crit Rev Eukaryot Gene Expr. 2009;19(1):73–88.PubMedCrossRef
35.
Inestrosa NC, Varela-Nallar L. Wnt signaling in the nervous system and in Alzheimer’s disease. J Mol Cell Biol. 2014;6(1):64–74.PubMedCrossRef
36.
Dengler-Crish CM, et al. Evidence of Wnt/beta-catenin alterations in brain and bone of a tauopathy mouse model of Alzheimer’s disease. Neurobiol Aging. 2018;67:148–58.PubMedCrossRef
37.
38.
Colnot CI, Helms JA. A molecular analysis of matrix remodeling and angiogenesis during long bone development. Mech Dev. 2001;100(2):245–50.PubMedCrossRef
39.
Gerstenfeld LC, et al. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J Cell Biochem. 2003;88(5):873–84.PubMedCrossRef
40.
Saran U, Gemini Piperni S, Chatterjee S. Role of angiogenesis in bone repair. Arch Biochem Biophys. 2014;561:109–17.PubMedCrossRef
41.
42.
Claudio L. Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer’s disease patients. Acta Neuropathol. 1996;91(1):6–14.PubMedCrossRef
43.
Kalaria RN, Hedera P. Differential degeneration of the cerebral microvasculature in Alzheimer’s disease. NeuroReport. 1995;6(3):477–80.PubMedCrossRef
44.
Mancardi GL, et al. Thickening of the basement membrane of cortical capillaries in Alzheimer’s disease. Acta Neuropathol. 1980;49(1):79–83.PubMedCrossRef
45.
46.
Suter OC, et al. Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke. 2002;33(8):1986–92.PubMedCrossRef
47.
Kalaria RN, et al. Vascular endothelial growth factor in Alzheimer’s disease and experimental cerebral ischemia. Brain Res Mol Brain Res. 1998;62(1):101–5.PubMedCrossRef
48.
Tarkowski E, et al. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer’s disease and vascular dementia. Neurobiol Aging. 2002;23(2):237–43.PubMedCrossRef
49.
Horner A, et al. Immunolocalisation of vascular endothelial growth factor (VEGF) in human neonatal growth plate cartilage. J Anat. 1999;194(Pt 4):519–24.PubMedPubMedCentralCrossRef
50.
Imai K, et al. Selective transendothelial migration of hematopoietic progenitor cells: a role in homing of progenitor cells. Blood. 1999;93(1):149–56.PubMedCrossRef
51.
Imai K, et al. Selective secretion of chemoattractants for haemopoietic progenitor cells by bone marrow endothelial cells: a possible role in homing of haemopoietic progenitor cells to bone marrow. Br J Haematol. 1999;106(4):905–11.PubMedCrossRef
52.
Peled A, et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood. 2000;95(11):3289–96.PubMedCrossRef
53.
Tan ZS, et al. Bone mineral density and the risk of Alzheimer disease. Arch Neurol. 2005;62(1):107–11.PubMedCrossRef
54.
55.
Zhao Y, Shen L, Ji HF. Alzheimer’s disease and risk of hip fracture: a meta-analysis study. Sci World J. 2012;2012:872173.CrossRef
56.
Yaffe K, et al. Association between bone mineral density and cognitive decline in older women. J Am Geriatr Soc. 1999;47(10):1176–82.PubMedCrossRef
57.
Zhou R, et al. Bone loss and osteoporosis are associated with conversion from mild cognitive impairment to Alzheimer’s disease. Curr Alzheimer Res. 2014;11(7):706–13.PubMedCrossRef
58.
Brownbill RA, Ilich JZ. Cognitive function in relation with bone mass and nutrition: cross-sectional association in postmenopausal women. BMC Womens Health. 2004;4(1):2.PubMedPubMedCentralCrossRef
59.
Lary CW, et al. Bone mineral density and the risk of incident dementia: a meta-analysis. J Am Geriatr Soc. 2023.
60.
Castro-Aldrete L, et al. Sex and gender considerations in Alzheimer’s disease: the Women’s Brain Project contribution. Front Aging Neurosci. 2023;15:1105620.PubMedPubMedCentralCrossRef
61.
62.
Lebrun CE, et al. Endogenous oestrogens are related to cognition in healthy elderly women. Clin Endocrinol (Oxf). 2005;63(1):50–5.PubMedCrossRef
63.
Hoskin EK, et al. Elevated sex-hormone binding globulin in elderly women with Alzheimer’s disease. Neurobiol Aging. 2004;25(2):141–7.PubMedCrossRef
64.
Yaffe K, et al. Cognitive decline in women in relation to non-protein-bound oestradiol concentrations. Lancet. 2000;356(9231):708–12.PubMedCrossRef
65.
Schupf N, et al. Onset of dementia is associated with age at menopause in women with Down’s syndrome. Ann Neurol. 2003;54(4):433–8.PubMedCrossRef
66.
Barrett-Connor E, et al. Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study. J Am Geriatr Soc. 1999;47(6):685–91.PubMedCrossRef
67.
Geerlings MI, et al. Endogenous estradiol and risk of dementia in women and men: the Rotterdam Study. Ann Neurol. 2003;53(5):607–15.PubMedCrossRef
68.
69.
70.
71.
72.
Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21(2):115–37.PubMed
73.
Riggs BL, Khosla S, Melton LJ 3rd. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res. 1998;13(5):763–73.PubMedCrossRef
74.
Manolagas SC, O’Brien CA, Almeida M. The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol. 2013;9(12):699–712.PubMedPubMedCentralCrossRef
75.
Katznelson L, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab. 1996;81(12):4358–65.PubMed
76.
77.
Falahati-Nini A, et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest. 2000;106(12):1553–60.PubMedPubMedCentralCrossRef
78.
Lee K, et al. Endocrinology: bone adaptation requires oestrogen receptor-alpha. Nature. 2003;424(6947):389.PubMedCrossRef
79.
•• Xiong J, et al. FSH blockade improves cognition in mice with Alzheimer’s disease. Nature 2022;603(7901):470–476. This study shows the potential of FSH blocking as a new treatment for AD, as this treatment in mice led to a reduction of AD phenotype.
80.
Geng W, et al. Immunization with FSHbeta fusion protein antigen prevents bone loss in a rat ovariectomy-induced osteoporosis model. Biochem Biophys Res Commun. 2013;434(2):280–6.PubMedCrossRef
81.
82.
83.
• Gera S, et al. FSH-blocking therapeutic for osteoporosis. Elife. 2022;11:e78022. https://​doi.​org/​10.​7554/​eLife.​78022. This study discussed the efficacy of FSH blockade in osteoporosis treatment in mice and introduced a new FSH-blocking antibody to be used in human trials.
84.
85.
86.
87.
88.
89.
90.
Olabarria M, et al. Age-dependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer’s disease mouse model: mechanism for deficient glutamatergic transmission? Mol Neurodegener. 2011;6:55.PubMedPubMedCentralCrossRef
91.
Kovacs GG, et al. Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol. 2016;131(1):87–102.PubMedCrossRef
92.
McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev. 1995;21(2):195–218.PubMedCrossRef
93.
McGeer PL, Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer’s disease. Neurology. 1992;42(2):447–9.PubMedCrossRef
94.
Otero K, et al. TREM2 and beta-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis. J Immunol. 2012;188(6):2612–21.PubMedCrossRef
95.
Humphrey MB, et al. TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function. J Bone Miner Res. 2006;21(2):237–45.PubMedCrossRef
96.
Essex AL, et al. Triggering receptor expressed on myeloid cells 2 (TREM2) R47H variant causes distinct age- and sex-dependent musculoskeletal alterations in mice. J Bone Miner Res. 2022;37(7):1366–81.PubMedCrossRef
97.
98.
Cassidy L, et al. Oxidative stress in Alzheimer’s disease: a review on emergent natural polyphenolic therapeutics. Complement Ther Med. 2020;49:102294.PubMedCrossRef
99.
100.
Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. Curr Med Chem. 2005;12(10):1161–208.PubMedCrossRef
101.
Mark RJ, et al. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J Neurochem. 1997;68(1):255–64.PubMedCrossRef
102.
103.
Keller JN, et al. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: role of the lipid peroxidation product 4-hydroxynonenal. J Neurochem. 1997;69(1):273–84.PubMedCrossRef
104.
Mattson MP, Chan SL. Neuronal and glial calcium signaling in Alzheimer’s disease. Cell Calcium. 2003;34(4–5):385–97.PubMedCrossRef
105.
Tamagno E, et al. H2O2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK. Exp Neurol. 2003;180(2):144–55.PubMedCrossRef
106.
Kimball JS, Johnson JP, Carlson DA. Oxidative stress and osteoporosis. J Bone Joint Surg Am. 2021;103(15):1451–61.PubMedCrossRef
107.
Fontani F, et al. Glutathione, N-acetylcysteine and lipoic acid down-regulate starvation-induced apoptosis, RANKL/OPG ratio and sclerostin in osteocytes: involvement of JNK and ERK1/2 signalling. Calcif Tissue Int. 2015;96(4):335–46.PubMedCrossRef
108.
Filaire E, Toumi H. Reactive oxygen species and exercise on bone metabolism: friend or enemy? Joint Bone Spine. 2012;79(4):341–6.PubMedCrossRef
109.
Romagnoli C, et al. Role of GSH/GSSG redox couple in osteogenic activity and osteoclastogenic markers of human osteoblast-like SaOS-2 cells. FEBS J. 2013;280(3):867–79.PubMedCrossRef
110.
Bai XC, et al. Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-kappaB. Biochem Biophys Res Commun. 2004;314(1):197–207.PubMedCrossRef
111.
112.
113.
114.
Al-Dujaili SA, et al. Apoptotic osteocytes regulate osteoclast precursor recruitment and differentiation in vitro. J Cell Biochem. 2011;112(9):2412–23.PubMedCrossRef
115.
Mulcahy LE, et al. RANKL and OPG activity is regulated by injury size in networks of osteocyte-like cells. Bone. 2011;48(2):182–8.PubMedCrossRef
116.
117.
Eldufani J, Blaise G. The role of acetylcholinesterase inhibitors such as neostigmine and rivastigmine on chronic pain and cognitive function in aging: a review of recent clinical applications. Alzheimers Dement (N Y). 2019;5:175–83.PubMedCrossRef
118.
119.
120.
121.
122.
123.
Beshir SA, et al. Aducanumab therapy to treat Alzheimer’s disease: a narrative review. Int J Alzheimers Dis. 2022;2022:9343514.PubMedPubMedCentral
124.
125.
Nicholls AR, Holt RI. Growth hormone and insulin-like growth factor-1. Front Horm Res. 2016;47:101–14.PubMedCrossRef
126.
de Vernejoul MC, et al. Evidence for defective osteoblastic function. A role for alcohol and tobacco consumption in osteoporosis in middle-aged men. Clin Orthop Relat Res. 1983;179:107–15.CrossRef
127.
128.
Bi H, et al. Key triggers of osteoclast-related diseases and available strategies for targeted therapies: a review. Front Med (Lausanne). 2017;4:234.PubMedCrossRef
129.
Makino A, et al. Abaloparatide exerts bone anabolic effects with less stimulation of bone resorption-related factors: a comparison with teriparatide. Calcif Tissue Int. 2018;103(3):289–97.PubMedPubMedCentralCrossRef
130.
• Zhang M, Hu S, Sun X. Alzheimer’s disease and impaired bone microarchitecture, regeneration and potential genetic links. Life (Basel). 2023;13(2):373. https://​doi.​org/​10.​3390/​life13020373. This is a comprehensive review article that explores mechanisms and genetic influences shared between AD and osteoporosis.
131.
Melton LJ 3rd, et al. Fracture risk in patients with Alzheimer’s disease. J Am Geriatr Soc. 1994;42(6):614–9.PubMedCrossRef
132.
Tolppanen AM, et al. Incident hip fractures among community dwelling persons with Alzheimer’s disease in a Finnish nationwide register-based cohort. PLoS ONE. 2013;8(3):e59124.PubMedPubMedCentralCrossRef
133.
134.
Sato Y, et al. Risk factors for hip fracture among elderly patients with Alzheimer’s disease. J Neurol Sci. 2004;223(2):107–12.PubMedCrossRef
135.
Kipen E, et al. Bone density, vitamin D nutrition, and parathyroid hormone levels in women with dementia. J Am Geriatr Soc. 1995;43(10):1088–91.PubMedCrossRef
136.
Morrison RS, Siu AL. Mortality from pneumonia and hip fractures in patients with advanced dementia. JAMA. 2000;284(19):2447–8.PubMedCrossRef
137.
138.
Matsueda M, Ishii Y. The relationship between dementia score and ambulatory level after hip fracture in the elderly. Am J Orthop (Belle Mead NJ). 2000;29(9):691–3.PubMed
139.
Tanaka S, et al. The Fracture and Immobilization Score (FRISC) for risk assessment of osteoporotic fracture and immobilization in postmenopausal women–a joint analysis of the Nagano, Miyama, and Taiji Cohorts. Bone. 2010;47(6):1064–70.PubMedCrossRef
140.
Baker NL, et al. Hip fracture risk and subsequent mortality among Alzheimer’s disease patients in the United Kingdom, 1988–2007. Age Ageing. 2011;40(1):49–54.PubMedCrossRef
141.
Bukata SV, Kates SL, O’Keefe RJ. Short-term and long-term orthopaedic issues in patients with fragility fractures. Clin Orthop Relat Res. 2011;469(8):2225–36.PubMedPubMedCentralCrossRef
142.
Gleason LJ, et al. Diagnosis and treatment of osteoporosis in high-risk patients prior to hip fracture. Geriatr Orthop Surg Rehabil. 2012;3(2):79–83.PubMedPubMedCentralCrossRef
143.
Kim SY, et al. Increased risk of dementia after distal radius, hip, and spine fractures. Medicine (Baltimore). 2020;99(10):e19048.PubMedCrossRef
144.
Goto S, et al. Relationship between cognitive function and balance in a community-dwelling population in Japan. Acta Otolaryngol. 2018;138(5):471–4.PubMedCrossRef
145.
Deschamps T, et al. Postural control and cognitive decline in older adults: position versus velocity implicit motor strategy. Gait Posture. 2014;39(1):628–30.PubMedCrossRef
146.
Bahureksa L, et al. The impact of mild cognitive impairment on gait and balance: a systematic review and meta-analysis of studies using instrumented assessment. Gerontology. 2017;63(1):67–83.PubMedCrossRef
147.
Kristinsdottir EK, Jarnlo GB, Magnusson M. Asymmetric vestibular function in the elderly might be a significant contributor to hip fractures. Scand J Rehabil Med. 2000;32(2):56–60.PubMedCrossRef
148.
Kristinsdottir EK, et al. Observation of vestibular asymmetry in a majority of patients over 50 years with fall-related wrist fractures. Acta Otolaryngol. 2001;121(4):481–5.PubMedCrossRef
149.
Ekvall Hansson E, Dahlberg LE, Magnusson M. Vestibular rehabilitation affects vestibular asymmetry among patients with fall-related wrist fractures - a randomized controlled trial. Gerontology. 2015;61(4):310–8.PubMedCrossRef
150.
Yu MD, Su BH, Zhang XX. Morphologic and molecular alteration during tibia fracture healing in rat. Eur Rev Med Pharmacol Sci. 2018;22(5):1233–40.PubMed
151.
152.
Neerland BE, et al. Associations between delirium and preoperative cerebrospinal fluid C-reactive protein, interleukin-6, and interleukin-6 receptor in individuals with acute hip fracture. J Am Geriatr Soc. 2016;64(7):1456–63.PubMedCrossRef
153.
Darweesh SKL, et al. Inflammatory markers and the risk of dementia and Alzheimer’s disease: a meta-analysis. Alzheimers Dement. 2018;14(11):1450–9.PubMedCrossRef
154.
Yeler H, Tahtabas F, Candan F. Investigation of oxidative stress during fracture healing in the rats. Cell Biochem Funct. 2005;23(2):137–9.PubMedCrossRef
155.
Mecocci P, et al. A long journey into aging, brain aging, and Alzheimer’s disease following the oxidative stress tracks. J Alzheimers Dis. 2018;62(3):1319–35.PubMedPubMedCentralCrossRef
156.
Piirtola M, et al. Fractures as an independent predictor of functional decline in older people: a population-based study with an 8-year follow-up. Gerontology. 2012;58(4):296–304.PubMedCrossRef
157.
Olofsson B, et al. Development of dementia in patients with femoral neck fracture who experience postoperative delirium-a three-year follow-up study. Int J Geriatr Psychiatry. 2018;33(4):623–32.PubMedCrossRef
Metadata
Title
Mind Gaps and Bone Snaps: Exploring the Connection Between Alzheimer’s Disease and Osteoporosis
Authors
Hannah S. Wang
Sonali J. Karnik
Tyler J. Margetts
Lilian I. Plotkin
Alexandru Movila
Jill C. Fehrenbacher
Melissa A. Kacena
Adrian L. Oblak
Publication date
18-01-2024
Publisher
Springer US
Published in
Current Osteoporosis Reports
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-023-00851-1